Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 03, 2020
"Para-retinal" Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression.
Journal: Molecular therapy. Methods & clinical development
Published: April 01, 2020
Trans-Ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Transduction in Large Animal Eye After Intravitreal Vector Administration.
Journal: Translational vision science & technology
Published: December 02, 2019
Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 05, 2018
Intravitreal Ciliary Neurotrophic Factor Transiently Improves Cone-Mediated Function in a CNGB3-/- Mouse Model of Achromatopsia.
Journal: Investigative ophthalmology & visual science
Published: November 17, 2015
Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice.
Journal: Molecular therapy. Methods & clinical development
Published: November 08, 2015
Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis.
Journal: Cold Spring Harbor perspectives in medicine
Published: June 24, 2015
Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits.
Journal: Human gene therapy. Clinical development
Published: September 12, 2014
CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function.
Journal: Investigative ophthalmology & visual science
Published: September 11, 2014
Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications.
Journal: PloS one
Published: March 11, 2014
Persistent expression of PEDF in the eye using high-capacity adenovectors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 02, 2008
Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.
Journal: Molecular vision
Published: September 04, 2008
Last Updated: 09/26/2026